The first attempts to develop a tetraspanin-targeted therapy predate the approval of rituximab by nearly a decade, when 131I –labeled murine anti-CD37 antibody was tested in a small cohort of non-Hodgkin lymphoma (NHL) patients (Press et al., 1989). Here, CD37 is linked to non-Hodgkin lymphoma.